May. 5 at 11:22 AM
$APTO Aptose Biosciences reports data from Phase 1/2 TUSCANY trial
Aptose Biosciences reported updated and new data from Aptose's Phase 1/2 TUSCANY trial in newly diagnosed acute myeloid leukemia patients dosed with a 40 mg or 80 mg dose of tuspetinib in combination with standard of care dosing of venetoclax and azacitidine. The TUS+VEN+AZA triplet is being developed as a safe and mutation agnostic frontline therapy to treat large, mutationally diverse populations of newly diagnosed AML patients who are ineligible to receive induction chemotherapy.
Earlier this year, Aptose announced the initiation of the TUSCANY trial and dosing in newly diagnosed AML patients at an initial dose of 40 mg TUS in the first cohort of four patients. The second cohort of patients is now receiving 80 mg TUS. Data from the first two cohorts, with a 40 mg or 80 mg dose of tuspetinib in the TUS+VEN+AZA combination, reveal promising clinical safety and antileukemic activity. To date, four newly diagnosed AML patients received the initial dose of TUS as part of the combination. Notably, a patient with biallelic TP53 mutations and a complex karyotype and FLT3-wildtype achieved a complete remission (CR) and the clinical site reported no measurable residual disease in this patient.
One FLT3-wildtype patient having an IDH-2 mutation achieved a CR and MRD-negative status. Another FLT3-wildtype patient achieved a CRi during Cycle 1 and MRD-negative status. The first three patients continue on treatment, while a fourth patient did not respond at this 40 mg dose level of TUS and was discontinued. The 40 mg dose of the TUS+VEN+AZA triplet remains safe, and no dose-limiting toxicities have been reported. To date, three newly diagnosed AML patients having diverse mutation profiles have received the 80 mg of TUS, as part of the TUS+VEN+AZA combination. The 80 mg TUS dose has been considered the optimal dose that has demonstrated safety and consistent blood exposure levels that exert potent antileukemic activity.
All patients achieved blast reductions in Cycle 1 that met the criteria for complete remissions and continue on treatment. Notably, another TP53-mutated/CK and FLT3-wildtype patient achieved blast reductions that met CRi criteria in Cycle 1 and is now receiving additional therapy in Cycle 2. The second patient, having FLT3-wildtype status, achieved a CR. The third patient, having FLT3-ITD and NPM1 mutations and entering the trial with a 75% bone marrow blast count, achieved a CRi. All three patients are early in their course of treatment and are expected to show further improvements in their disease status as they are all continuing with treatment, and MRD status will be monitored as the patients move through their courses of therapy.
The 80 mg dose of TUS, as part of the TUS+VEN+AZA triplet, continues to show favorable safety with no dose-limiting toxicities having been reported. "The treatment paradigm for AML is shifting to triplet combination therapy," said Rafael Bejar, CMO. "We have always maintained that tuspetinib, with its notable safety profile and ability to treat the larger, difficult-to-treat AML populations with high-risk mutations, could be an ideal drug for a triplet combination therapy in the frontline setting. With the majority of patients already achieving complete responses -- including early responses in patients with adverse mutations -- the clinical findings to date are bearing that out."
